Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies

EXTON, Pa., Jan. 15 /PRNewswire-FirstCall/ -- Isolagen(TM), Inc. (Amex: ILE) announced today that injections have been completed in the pivotal Phase III multi-center, double-blind, randomized, placebo-controlled clinical trials evaluating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles (Studies IT-A-005 and IT-A-006). Subjects have advanced to the follow-up period of the study.

Isolagen also announced the completion of injections in the Phase II open label study designed to gather further safety and potential application information on the use of the Isolagen Therapy(TM) for the full face (Study IT-A-007). The subjects in this study also have advanced to the follow-up period.

"These are important clinical milestones to Isolagen, especially the advancement of our lead Phase III pivotal wrinkle study to the follow-up period of the trial," said Declan Daly, Chief Executive Officer of Isolagen, Inc.

About Isolagen, Inc.

Isolagen(TM), Inc. (AMEX: ILE) is an aesthetic and therapeutic company committed to developing and commercializing scientific advances and innovative technologies. The company's technology platform includes the Isolagen Process(TM), a cell processing system for skin and tissue rejuvenation which is currently in clinical development for a broad range of aesthetic and therapeutic applications including wrinkles, acne scars, burns and periodontal disease. Isolagen also commercializes a scientifically-advanced line of skincare systems through its majority-owned subsidiary, Agera(R) Laboratories, Inc. For additional information, please visit www.isolagen.com .

Isolagen Forward Looking Statements

All statements in this news release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q. We operate in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's Annual Report on Form 10-K for the year ended December 31, 2006, as well as other public filings with the SEC since such date.

SOURCE Isolagen, Inc.

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.